Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.
第一作者:
Prathap,Nagaraja Shastri
第一单位:
Clinical Pharmacology and Pharmacometrics, Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania, USA.
作者:
主题词
人类(Humans);抗体, 双特异性(Antibodies, Bispecific);T淋巴细胞(T-Lymphocytes);肿瘤(Neoplasms);制药工业(Drug Industry);最大耐受剂量(Maximum Tolerated Dose);动物(Animals)
DOI
10.1002/cpt.3439
PMID
39295563
发布时间
2024-12-18
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文